Last updated: February 12, 2026
rket Analysis and Price Projections for NDC: 00068-0597
Overview
NDC 00068-0597 corresponds to Umeclidinium inhalation powder, marketed as Incruse Ellipta by GlaxoSmithKline (GSK). It is approved for the maintenance treatment of COPD, including chronic bronchitis and emphysema. The drug is a long-acting muscarinic antagonist (LAMA) delivered via the Ellipta inhaler system.
Market Size and Key Drivers
The COPD treatment market has shown consistent growth. In 2022, the global COPD market was valued at approximately $11.2 billion and is projected to expand at a compound annual growth rate (CAGR) of 4.8% through 2027 [1].
Umeclidinium’s market penetration is significant within the LAMA segment owing to its efficacy profile, inhaler convenience, and GSK’s marketing strength.
Competitive Landscape
Main competitors include:
- Tiotropium (Spinhaler, Spiriva)
- Aclidinium (Tudorza Pressair)
- Umeclidinium/vilanterol (Anoro Ellipta) – combination therapy
- Tiotropium/olodaterol (Stiolto Respimat)
Umeclidinium gains market share from Tiotropium due to comparable efficacy but advantages in inhaler device design.
Market Penetration & Adoption Trends
In the U.S., Umeclidinium has approximately a 15-20% share of the LAMA monotherapy segment as of 2023. Market penetration is driven by formulary coverage, prescriber comfort, and patient adherence facilitated by the Ellipta device.
Pricing Analysis
| Parameter |
Details |
| Average Wholesale Price (AWP) |
$420–$450 per inhaler (30-unit dose pack) |
| Average Selling Price (ASP) |
$385–$410 per pack |
| Insurance Reimbursement Rate |
Approximately 85% of ASP |
| Patient Co-pay |
$20–$45 depending on insurance plan |
Price Trends & Projections
Umeclidinium’s price has been relatively stable from 2020–2023, with slight reductions for generic or biosimilar entries. Future pricing depends on patent expiry timelines and emergence of generics or biosimilars.
Patent & Regulatory Considerations
GSK’s composition patent for Umeclidinium occupies exclusivity until at least 2025. Patent cliffs typically lead to price erosion, with biosimilar competition potentially reducing Umeclidinium prices by 20–35% within 1–3 years post-patent expiration [2].
Forecasting Scenarios
-
Base Case:
Assuming steady market share growth, minimal competition, and no major patent challenges, pricesdrž retain current levels through 2025.
Market volume grows at 4–5% annually; revenues could reach approximately $500 million in the U.S. by 2025.
-
Post-Patent Expiry:
Biosimilar entry anticipated post-2025 could decrease unit prices by approximately 25%. Market share could shift; revenue projections could decrease 30–35% in the following 2 years, but overall market volume might compensate for price reductions due to expanded patient access.
-
Competitive Disruption:
Introduction of a superior combination product or new delivery technology might further impact Umeclidinium’s market position, potentially reducing revenue growth projections to 2–3% annually beyond 2025.
Implications for Stakeholders
- Investors: Expect sustained revenues through 2025, followed by potential price and market share contractions post-patent expiry.
- Manufacturers: Consider biosimilar development pathways and patent litigation strategies to extend market exclusivity.
- Healthcare Providers: Cost management initiatives and formulary decisions will influence patient access and drug utilization.
Key Takeaways
- Umeclidinium (NDC: 00068-0597) holds a meaningful share in the COPD inhaler market with stable pricing through 2023.
- Market growth is driven by COPD prevalence, inhaler device preference, and formulation efficacy.
- Price erosion is expected after patent expiry, with biosimilar entries likely to reduce prices by approximately 25–35% within 2–3 years.
- Market dynamics will depend on competitive innovations, regulatory developments, and payer strategies.
FAQs
-
When does Umeclidinium’s patent expire?
Patents typically expire around 2025, but patent litigation and additional patent filings could extend exclusivity.
-
What factors influence Umeclidinium’s pricing?
Market competition, patent status, manufacturing costs, negotiated rebates, and formulary placement.
-
How does biosimilar entry affect market pricing?
Biosimilars can decrease prices by 20–35% within 1-3 years of patent expiration, depending on market uptake.
-
What is the primary growth driver for Umeclidinium?
An increasing prevalence of COPD and patient switching from less effective agents to inhalers with better adherence profiles.
-
Are there emerging competitors or formulations that threaten Umeclidinium?
Yes. Fixed-dose combinations and novel delivery systems could impact the monotherapy segment’s market share.
References
[1] Research and Markets, "Global COPD Market Forecasts," 2023.
[2] IQVIA, "Patent Expiry and Biosimilar Entry," 2022.
